Search results
Results From The WOW.Com Content Network
Impact Factor. The Impact Factor measures the average number of citations in a particular year by papers published in the journal in the two preceding years. 5-Year Impact Factor. The 5-Year Impact Factor is the average number of times articles from the journal published in the past five years have been cited in the JCR year.
The new journal Impact Factors (Journal Citation Reports, 2021), announced on June 28, 2022, reflect growing usage and citations across new and established Cell Press titles, both in open access and hybrid publishing.
The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) metric.
Cell is a journal covering the technologies/fields/categories related to Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1). It is published by Elsevier B.V.. The overall rank of Cell is 6. According to SCImago Journal Rank (SJR), this journal is ranked 24.342.
View all Cell Press Selections. Publisher of over 50 scientific journals across the life, physical, earth, and health sciences, both independently and in partnership with scientific societies including Cell, Neuron, Immunity, Current Biology, AJHG, and the Trends Journals.
Cell Journal Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 2228-5806.
The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) metric.
The Journal Impact Factor is defined as all citations to the journal in the current JCR year to items published in the previous two years, divided by the total number of scholarly items...
Experimental workflow of MitoT to native and CAR engineered T cells. Credit: Journal of Translational Medicine (2024). DOI: 10.1186/s12967-024-05627-4
Recent findings suggest that immunoradiotherapy (IRT), combining photon radiotherapy (XRT) or proton radiotherapy (PRT) with immune checkpoint blockade, can enhance systemic tumor control. However, the comparative efficacy of XRT and PRT in IRT remains understudied. To address this, we compared outcomes between XRT + αPD1 and PRT + αPD1 in murine αPD1-resistant lung cancer (344SQR).